Combination targeted adjuvant therapy with dabrafenib and trametinib doubles relapse-free survival in patients with stage III BRAF-mutant melanoma, according to late-breaking results from the COMBI-AD trial presented today ...
Sep 11, 2017
0
0
The initiating oncogenic event in almost half of human lung adenocarcinomas is still unknown, complicating the development of selective targeted therapies. Yet these tumours harbour a number of alterations without obvious ...
Aug 3, 2017
0
5
Clinical trial results presented in an oral abstract session 3:00pm Monday, June 5 at the American Society for Clinical Oncology (ASCO) Annual Meeting 2017 shows promising results for the addition of vemurafenib (anti-BRAF) ...
Jun 5, 2017
0
2
Penn State College of Medicine researchers have shown, for the first time, a possible correlation between the partial meltdown of the Three Mile Island Nuclear Generating Station and thyroid cancers in the counties surrounding ...
May 31, 2017
0
1
A type of targeted therapy that has shown promising results treating advanced melanoma could also be used to help speed up how the skin repairs itself from injury, UCLA researchers have found, providing a potential new way ...
Aug 1, 2016
0
7
In the era of precision medicine, targeting the mutations driving cancer growth, rather than the tumor site itself, continues to be a successful approach for some patients. In the latest example, researchers from Penn Medicine ...
Jul 23, 2016
0
27
Testing for BRAF V600 mutations in cell-free DNA from plasma using the PCR-based IdyllaTM BRAF Mutation Test was feasible and concordant with standard tests of archival tumor biopsy samples and had a short turnaround time ...
May 23, 2016
0
0
An international collaborative study led by scientists at the Sanford Burnham Prebys Medical Discovery Institute (SBP) has identified a malicious form of a protein that drives the formation of melanoma. The findings, published ...
May 19, 2016
0
10
A University of Colorado Cancer study published today in the Journal of the American Medical Informatics Association (JAMIA) describes a new tool that interprets the raw data of whole exome tumor sequencing and then matches ...
Mar 29, 2016
0
0
A team led by Massachusetts General Hospital (MGH) investigators has reported the first successful use of a targeted therapy drug to treat a patient with a debilitating, recurrent brain tumor. In a paper published online ...
Nov 6, 2015
0
68
